Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. (Q48507006)

12 February 2018

meta-analysis

0 references

title

Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. (English)

1 reference

12 February 2018

0 references

0 references

1

1 reference

12 February 2018

Johann Steiner

2

1 reference

12 February 2018

Michael Berk

object named as

M Berk

3

0 references

author name string

M L Molendijk

4

1 reference

12 February 2018

A Gonzalez-Pinto

5

1 reference

12 February 2018

C W Turck

6

1 reference

12 February 2018

P Nardin

7

1 reference

12 February 2018

C-A Gonçalves

8

1 reference

12 February 2018

language of work or name

English

0 references

publication date

30 September 2014

1 reference

12 February 2018

published in

Molecular Psychiatry

1 reference

12 February 2018

volume

20

1 reference

12 February 2018

issue

9

1 reference

12 February 2018

page(s)

1108-1119

1 reference

12 February 2018

https://scigraph.springernature.com/pub.10.1038/mp.2014.117

exact match

0 references

cites work

Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

BDNF-TrkB signaling and neuroprotection in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

RETRACTED: Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Transport of brain-derived neurotrophic factor across the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased serum brain-derived neurotrophic factor levels in major depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Brain derived neurotropic factor in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Trauma profile in Egyptian adolescents with first-episode schizophrenia: relation to psychopathology and plasma brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Language bias in randomised controlled trials published in English and German.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: an overview and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Evidence-based pharmacotherapy of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

A simple method for obtaining original data from published graphs and plots

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Assessing publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Cumulative meta-analysis: a new tool for detection of temporal trends and publication bias in ecology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Relationship between Brain-Derived Neurotrophic Factor and Schneiderian First Rank Symptoms in Antipsychotic-Naïve Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Lifestyle modification and behavior therapy effectively reduce body weight and increase serum level of brain-derived neurotrophic factor in obese non-diabetic patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Plasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

BDNF serum concentrations in first psychotic episode drug-naïve schizophrenic patients: associations with personality and BDNF Val66Met polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Effects of antipsychotics on the serum BDNF levels in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Neuroprogression in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Evidence for a release of brain-derived neurotrophic factor from the brain during exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

The impact of age, weight and gender on BDNF levels in human platelets and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Reduced platelet BDNF level in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Serum and plasma brain-derived neurotrophic factor (BDNF) in abstinent alcoholics and social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2014.117

Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia

21 January 2018

1 reference

12 December 2020

Purification and identification of brain-derived neurotrophic factor from human serum

1 reference

12 December 2020

Changes in Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor-Beta in Schizophrenic Patients Before and After Treatment

1 reference

12 December 2020

Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment

1 reference

12 December 2020

Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.

1 reference

12 December 2020

Brain-derived neurotrophic factor serum concentrations are increased in drug-naïve schizophrenic patients with chronic cannabis abuse and multiple substance abuse

1 reference

12 December 2020

Human platelets contain brain-derived neurotrophic factor.

1 reference

12 December 2020

Postnatal BDNF expression profiles in prefrontal cortex and hippocampus of a rat schizophrenia model induced by MK-801 administration

1 reference

12 December 2020

Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury

1 reference

12 December 2020

Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor

1 reference

12 December 2020

Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation.

1 reference

12 December 2020

The Brief Psychiatric Rating Scale for Children

1 reference

12 December 2020

Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: Lack of association in a pilot study

1 reference

12 December 2020

Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia

1 reference

12 December 2020

Identifiers

DOI

10.1038/MP.2014.117

1 reference

12 February 2018

PubMed ID

25266124

1 reference

12 February 2018